Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
302 questions in 48 reviews · Neuromuscular
current versionsNo studies 302 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Electroacupuncture vs night splints Overall clinical improvement at long‐term · carpal tunnel syndrome Acupuncture and related interventions for the treatment of symptoms associated with carpal tunnel syndrome (2018) · Cochrane | no estimate extracted | NR | No studies |
Acupuncture vs placebo/sham acupuncture Overall clinical improvement (at long‐term · carpal tunnel syndrome Acupuncture and related interventions for the treatment of symptoms associated with carpal tunnel syndrome (2018) · Cochrane | no estimate extracted | NR | No studies |
Acupuncture plus NSAID plus vitamins vs NSAID plus vitamins Overall clinical improvement at long‐term · carpal tunnel syndrome Acupuncture and related interventions for the treatment of symptoms associated with carpal tunnel syndrome (2018) · Cochrane | no estimate extracted | NR | No studies |
Acupuncture plus NSAID plus vitamins vs NSAID plus vitamins Adverse events · carpal tunnel syndrome Acupuncture and related interventions for the treatment of symptoms associated with carpal tunnel syndrome (2018) · Cochrane | no estimate extracted | NR | No studies |
Laser acupuncture vs placebo/sham laser acupuncture Overall clinical improvement at long‐term · carpal tunnel syndrome Acupuncture and related interventions for the treatment of symptoms associated with carpal tunnel syndrome (2018) · Cochrane | no estimate extracted | NR | No studies |
Absorbable vs non‐absorbable sutures Adverse outcomes including wound infection, scar breakdown or return to theatre Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery (2018) · Cochrane | no estimate extracted | NR | No studies |
Absorbable vs non‐absorbable sutures Postoperative scar satisfaction Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery (2018) · Cochrane | no estimate extracted | NR | No studies |
Absorbable vs non‐absorbable sutures Adverse outcomes including wound infection, scar breakdown or return to theatre Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery (2018) · Cochrane | no estimate extracted | NR | No studies |
Absorbable vs non‐absorbable sutures Postoperative pain: late pain (6 weeks postoperatively) Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery (2018) · Cochrane | no estimate extracted | NR | No studies |
Absorbable vs non‐absorbable sutures Postoperative hand function Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Change in disability after one year · people with chronic inflammatory demyelinating polyradiculoneuropathy Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (2017) · Cochrane | no estimate extracted | NR | No studies |
Monthly pulsed high‐dose dexamethasone vs oral prednisolone Change in disability after one year · people with chronic inflammatory demyelinating polyradiculoneuropathy Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (2017) · Cochrane | no estimate extracted | NR | No studies |
Interferon beta‐1a vs placebo Change in disability after 26 or more weeks · people with CIDP Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic… (2017) · Cochrane | no estimate extracted | NR | No studies |
Non‐invasive ventilation vs standard care Quality of life (SF‐36 PCS) · people with ALS Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Non‐invasive ventilation vs standard care Adverse events (not reported) · people with ALS Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy vs ultrasound Adverse events · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy vs fascial manipulation Overall improvement in CTS:SSS: long term ‐ not reported · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy vs fascial manipulation Overall improvement in CTS: FSS: long term · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy vs fascial manipulation Adverse events · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy and a splint vs ultrasound and a splint Overall improvement in CTS:SSS: long term ‐ not measured · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy and a splint vs ultrasound and a splint Overall improvement in CTS: FSS: long term ‐ not reported · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy and a splint vs ultrasound and a splint Adverse events · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy and a splint vs placebo and a splint Overall improvement in CTS: SSS: long term ‐ not measured · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy and a splint vs placebo and a splint Overall improvement in CTS: FSS: long term ‐ not measured · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy, wrist splint, and vitamin B6 vs placebo, wrist splint, and vitamin B6 Overall improvement in CTS: SSS: long term ‐ not measured · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy, wrist splint, and vitamin B6 vs placebo, wrist splint, and vitamin B6 Overall improvement in CTS: FSS: long term ‐ not reported · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy, wrist splint, and vitamin B6 vs placebo, wrist splint, and vitamin B6 Adverse events · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy vs placebo Adverse events · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs placebo Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy Corticosteroids for the treatment of Duchenne muscular dystrophy (2016) · Cochrane | no estimate extracted | NR | No studies |
Deflazacort vs prednisone Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy Corticosteroids for the treatment of Duchenne muscular dystrophy (2016) · Cochrane | no estimate extracted | NR | No studies |
Deflazacort vs prednisone Muscle strength ‐ not reported · patients with Duchenne muscular dystrophy Corticosteroids for the treatment of Duchenne muscular dystrophy (2016) · Cochrane | no estimate extracted | NR | No studies |
Deflazacort vs prednisone Change in 10‐metre walking time · patients with Duchenne muscular dystrophy Corticosteroids for the treatment of Duchenne muscular dystrophy (2016) · Cochrane | no estimate extracted | NR | No studies |
Deflazacort vs prednisone Change in 4‐stair climbing time · patients with Duchenne muscular dystrophy Corticosteroids for the treatment of Duchenne muscular dystrophy (2016) · Cochrane | no estimate extracted | NR | No studies |
Deflazacort vs prednisone Fractures · patients with Duchenne muscular dystrophy Corticosteroids for the treatment of Duchenne muscular dystrophy (2016) · Cochrane | no estimate extracted | NR | No studies |
Weekend‐only vs daily prednisone Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy Corticosteroids for the treatment of Duchenne muscular dystrophy (2016) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs placebo Change in nerve pain and in nerve tenderness at 1 year ‐ not reported · people with nerve damage (6 to 24 months' duration) in leprosy Corticosteroids for treating nerve damage in leprosy (2016) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs placebo Limitations in activities of daily living at 1 year ‐ not reported · people with nerve damage (6 to 24 months' duration) in leprosy Corticosteroids for treating nerve damage in leprosy (2016) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs placebo Limitations in participation at 1 year ‐ not reported · people with nerve damage (6 to 24 months' duration) in leprosy Corticosteroids for treating nerve damage in leprosy (2016) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs placebo Improvement in motor nerve function at 1 year ‐ not reported · people with nerve damage (< 6 months' duration) in leprosy Corticosteroids for treating nerve damage in leprosy (2016) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs placebo Change in nerve pain and in nerve tenderness at 1 year ‐ not reported · people with nerve damage (< 6 months' duration) in leprosy Corticosteroids for treating nerve damage in leprosy (2016) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs placebo Limitations in activities of daily living at 1 year ‐ not reported · people with nerve damage (< 6 months' duration) in leprosy Corticosteroids for treating nerve damage in leprosy (2016) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs placebo Limitations in participation at 1 year ‐ not reported · people with nerve damage (< 6 months' duration) in leprosy Corticosteroids for treating nerve damage in leprosy (2016) · Cochrane | no estimate extracted | NR | No studies |
Antioxidant vs placebo Survival (not measured) · people with Friedreich ataxia Pharmacological treatments for Friedreich ataxia (2016) · Cochrane | no estimate extracted | NR | No studies |
Interferon beta‐1a vs placebo Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs placebo Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs placebo Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs placebo Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin vs placebo Change in muscle strength at 12 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate and anti‐T lymphocyte immunoglobulin vs methotrexate Change in muscle mass at 12 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate and anti‐T lymphocyte immunoglobulin vs methotrexate Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |